Prophylaxis and Treatment of Cancer-Associated Venous Thromboembolism - Comparison Hematologist/Oncologists versus Angiologist/Phlebologists

被引：0
|
作者：
Matzdorff, Axel [1 ]
Ledig, Bettina [2 ]
Stuecker, Markus [3 ]
Riess, Hanno [4 ]
机构：
[1] Asklepios Clin Uckermark, Dept Internal Med 2, Auguststr 23, D-16303 Schwedt Od, Germany
[2] LEO Pharma GmbH, Neu Isenburg, Germany
[3] Ruhr Univ Bochum, St Josef Hosp, Dept Dermatol, Bochum, Germany
[4] Charite Campus Virchow Clin, Med Clin Haematol Oncol, Berlin, Germany
来源：
ONCOLOGY RESEARCH AND TREATMENT | 2017年 / 40卷 / 03期
关键词：
Cancer-associated venous thromboembolism; Health services research; Hematologist; Oncologist; Angiologist Phlebologist; CLINICAL-PRACTICE GUIDELINES; DEEP-VEIN THROMBOSIS; ADHERENCE; RISK;
D O I：
10.1159/000456670
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：138 / 140
页数：3
相关论文
共 50 条
  • [41] Gender Differences in Cancer-associated Venous Thromboembolism
    Riondino, Silvia
    Guadagni, Fiorella
    Formica, Vincenzo
    Ferroni, Patrizia
    Roselli, Mario
    CURRENT MEDICINAL CHEMISTRY, 2017, 24 (24) : 2589 - 2601
  • [42] Treatment of cancer-associated venous thromboembolism in patients under palliative care
    Debourdeau, Philippe
    Sevestre, Marie-Antoinette
    Bertoletti, Laurent
    Mayeur, Didier
    Girard, Philippe
    Scotte, Florian
    Sanchez, Olivier
    Mahe, Isabelle
    ARCHIVES OF CARDIOVASCULAR DISEASES, 2024, 117 (01) : 94 - 100
  • [43] Efficacy and safety of Xa inhibitors for the treatment of cancer-associated venous thromboembolism
    Kimpton, Miriam
    Carrier, Marc
    EXPERT OPINION ON DRUG SAFETY, 2019, 18 (04) : 313 - 320
  • [44] Unmet clinical needs in the prevention and treatment of cancer-associated venous thromboembolism
    Giustozzi, Michela
    Franco, Laura
    Agnelli, Giancarlo
    Verso, Melina
    TRENDS IN CARDIOVASCULAR MEDICINE, 2023, 33 (06) : 336 - 343
  • [45] A systematic review of apixaban in prevention and treatment of cancer-associated venous thromboembolism
    Caputo, Ryan
    Pyle, Jacqueline
    Kuriakose, Philip
    Lekura, Jona
    JOURNAL OF THE AMERICAN PHARMACISTS ASSOCIATION, 2021, 61 (05) : E26 - E38
  • [46] Optimal anticoagulant treatment of cancer-associated venous thromboembolism remains unclear
    Al-Samkari, Hanny
    BMJ EVIDENCE-BASED MEDICINE, 2019, 24 (03) : 115 - 116
  • [47] Treatment of cancer-associated venous thromboembolism in the age of direct oral anticoagulants
    Ay, C.
    Beyer-Westendorf, J.
    Pabinger, I.
    ANNALS OF ONCOLOGY, 2019, 30 (06) : 897 - 907
  • [48] Rivaroxaban versus dalteparin for the treatment of cancer-associated venous thromboembolism: a systematic review and meta-analysis
    Shrestha, Bibek
    Bhusal, Suzit
    Kandel, Grishma
    Bastakoti, Sudip
    Yadav, Krishna Kumar
    ANNALS OF MEDICINE AND SURGERY, 2025, 87 (03): : 1617 - 1627
  • [49] Inpatient primary prophylaxis of cancer-associated thromboembolism (CAT)
    Butler, Taylor W.
    Ali, Nadeen T.
    Spalek, Mateusz J.
    Scott, Sara
    Tsoukalas, Nikolaos
    SUPPORTIVE CARE IN CANCER, 2022, 30 (10) : 8501 - 8509
  • [50] Inpatient primary prophylaxis of cancer-associated thromboembolism (CAT)
    Taylor W. Butler
    Nadeen T. Ali
    Mateusz J. Spalek
    Sara Scott
    Nikolaos Tsoukalas
    Supportive Care in Cancer, 2022, 30 : 8501 - 8509
12345